Note 8 - Fair Value of Financial Instruments (Tables)

3 Months Ended

Jun. 30, 2013

Note 8 - Fair Value of Financial Instruments (Tables) [Line Items]

Schedule of Interest Rate Derivatives [Table Text Block]

Swap Counterparty	Notional Amount		Effective Date	Maturity Date	Cash Settlement Date
Wells Fargo Bank, N.A.	$	25,000,000	4/15/2011	4/15/2021	9/22/2014
PNC Bank, N.A.	$	50,000,000	7/1/2011	7/1/2018	12/1/2013
Bank of Montreal	$	50,000,000	4/2/2012	4/1/2019	12/1/2013
Wells Fargo Bank, N.A.	$	25,000,000	4/2/2012	4/2/2019	9/22/2014
Royal Bank of Canada	$	25,000,000	4/1/2013	4/3/2023	10/31/2014

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
June 30, 2013:
Assets
Derivative financial instruments	$	—	$	1,379,186		$	—	$	1,379,186
Liabilities
Derivative financial instruments	$	—	$	(11,101,428	)	$	—	$	(11,101,428	)
December 31, 2012:
Liabilities
Derivative financial instruments	$	—	$	(18,012,516	)	$	—	$	(18,012,516	)

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]

Derivatives designed as hedging instruments	Balance sheet location	June 30, 2013  Fair Value			December 31, 2012 Fair Value
Interest rate products	Other assets	$	1,379,186		$	—
Interest rate products	Other liabilities	$	(11,101,428	)	$	(18,012,516	)

Cash Flow Hedges [Member]

Note 8 - Fair Value of Financial Instruments (Tables) [Line Items]

Derivative Instruments, Gain (Loss) [Table Text Block]

	Three Months Ended					Six Months Ended
	June 30, 2013		June 30, 2012			June 30, 2013		June 30, 2012
Amount of gain (loss) recognized in OCI on derivative	$	5,739,808	$	(5,441,029	)	$	6,062,062	$	(5,046,565	)
Amount of  loss reclassified from accumulated OCI into interest	$	1,172,818	$	960,075		$	2,370,502	$	1,532,151
Amount of gain recognized in income on derivative (ineffective portion and amount excluded from effectiveness testing)	$	41,927	$	37,947		$	4,567		12,296